Liquidia Corp (NASDAQ:LQDA)
| Market Cap | 2.51B+19.4% |
| Revenue (ttm) | 450.91M+2233.6% |
| Net Income | 138.61M+198.0% |
| EPS | 1.37+181.0% |
| Shares Out | 88.93M |
| PE Ratio | 18.32 |
| Forward PE | 12.05 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,457,593.732 |
| Open | 26.34 |
| Previous Close | 26.68 |
| Day's Range | 26.34 - 29.35 |
| 52-Week Range | 21.94 - 93.61 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 83.20(+195.14%) |
| Earnings Date | Nov 2, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About LQDA
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$LQDA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in LQDA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by LQDA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
LQDA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
LQDA Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Segment Information | $170.38M | 58.43% |
| Income (loss) from operations | $85.52M | 29.33% |
| Personnel, including stock-based compensation | $35.70M | 12.24% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New LQDA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to LQDA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in LQDA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $154.34M |
| IJRiShares Core S&P Small-Cap ETF | $118.48M |
| VXFVanguard Extended Market ETF | $55.64M |
| IWMiShares Russell 2000 ETF | $49.41M |
| VTWOVanguard Russell 2000 ETF | $27.65M |
| XSMOInvesco S&P SmallCap Momentum ETF | $22.65M |
Estimated from each fund’s disclosed top holdings × AUM
LQDA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from LQDA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score